Featured Clinical Trial: Ginger Treatment For Cancer-Related Nausea and Vomiting

2005 ◽  
Author(s):  
Keyword(s):  
Clinical Trial ◽  
Nausea And Vomiting

scholarly journals Efficacy of Three Different Prophylactic Treatments for Postoperative Nausea and Vomiting after Vitrectomy: A Randomized Clinical Trial

2019 ◽  
Vol 8 (3) ◽  
pp. 391 ◽  
Author(s):  
Michele Reibaldi ◽  
Matteo Fallico ◽  
Antonio Longo ◽  
Teresio Avitabile ◽  
Marinella Astuto ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Postoperative Pain ◽  
Adverse Events ◽  
Local Anesthesia ◽  
Postoperative Nausea ◽  
Therapy Group ◽  
Combined Therapy ◽  
Postoperative Nausea And Vomiting ◽  
Nausea And Vomiting ◽  
Combination Group

Postoperative nausea and vomiting (PONV) after vitreoretinal surgery may potentially be associated with severe complications, such as suprachoroidal hemorrhage. The purpose of the present multicenter clinical trial (NCT02386059) was to assess the efficacy of three different prophylactic treatments for PONV after vitrectomy under local anesthesia. Patients undergoing primary vitrectomy were randomized to the control arm or to one of the treatment arms (4 mg ondansetron, 4 mg dexamethasone, combination of the two drugs). The primary outcome measure was the proportion of complete response (no nausea, no vomiting, no retching, and no use of antiemetic rescue medication) during 24 h after vitrectomy. Secondary outcomes included the severity standardized score of PONV, postoperative pain standardized score, and rate of ocular and non-ocular adverse events. Baseline demographics of the 1287 patients were comparable between the four arms. The combined therapy group showed a statistically significant lower incidence of PONV compared to the placebo and monotherapy (p < 0.001). PONV severity was also reduced in the combination group compared to the others (p < 0.001). Postoperative pain scores and adverse events were comparable among the four groups. Combined therapy with dexamethasone and ondansetron was the most effective treatment for reducing the incidence and severity of PONV in patients undergoing vitrectomy under local anesthesia.

Planned release dihydroergotamine in common migraine and “tension-vascular headache”: multicentre clinical trial

Cephalalgia ◽  
1983 ◽  
Vol 3 (1_suppl) ◽  
pp. 189-191
Author(s):  
D. Fontanari ◽  
L. Perulli ◽  
F. Conte ◽  
E. Tambato ◽  
V. Toso ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Oral Dose ◽  
Nausea And Vomiting ◽  
Vascular Headache ◽  
Multicentre Clinical Trial ◽  
Sono Stati ◽  
Pharmaceutical Form ◽  
The Common ◽  
Digestive Disorders

The antimigraine efficacy of dihydroergotamine methanesulphonate in the pharmaceutical form of planned release capsules has been evaluated. Forty-nine subjects were treated, 39 suffering from common migraine 10 from tensive vascular headache, for a period of 90 days, with an oral dose of 15 mg twice daily. The product was found to be efficacious in 71% of the common migraine cases, while unsatisfactory or nil results were obtained in the remaining 29%. In the tensive-vascular headache cases, efficacy was 40% compared to 60% unsatisfactory or nil results. Tolerance was good in 43 cases, while transient digestive disorders (nausea and vomiting) occurred in 6; in 2 cases the treatment had to be withdrawn for allergic erythema. The results demonstrate that the drug is indicated in cases of common migraine, while it does not appear to significantly influence the course of attacks of tensive-vascular headache. On a etudié l'activité thérapeutique de la dihydroergotamine à action prolongée chez 49 malades porteurs de migraine commune (39 cas) et de céphalée tensive-vasculaire (10 cas), pendant 90 jours, à la dose de 5 mg deux fois par jour per os. Dans les cas de migraine commune le produit a été efficace dans 71% des cas, alors que dans 29% on a obtenu des résultats insuffisants ou des échecs. Dans les cas de cephalée tensive-vasculaire l'efficacité a été du 40%, contre un 60% de resultats insuffisants ou des échecs. La tolérance c'est averée bonne dans 43 cas, dans 6 cas ont été appreciés des troubles digestives (nausée et vomissement) transitoires et seulement dans 2 cas on a du interrompre le traitement pour intolérance (érythème allergique). Les résultats montrent que le produit constitue une bonne indication dans les cas de migraine commune, alors qu'il ne semble pas être en mesure de modifier significativement le cours des crises de cephalée tensive-vasculaire. Si è valutata l'efficacia antiemicranica della diidroergotamina metansulfonato nella forma farmaceutica in capsule a cessione programmata. Sono stati trattati 49 soggetti, di cui 39 affeti da emicrania comune e 10 da cefalea tensivo-vascolare, per un periodo di 90 giorni, alla dose di 15 mg due volte al giorno per os. Nei casi di emicrania comune il prodotto si è dimostrato efficace nel 71%, mentre nel 29% si sono avuti risultati insufficienti o nulli. Nei casi di cefalea tensivo-vascolare l'efficacia è stata del 40%, contro un 60% di risultati insufficienti o nulli. La tolleranza è stata buona in 43 casi, in 6 casi si sono avuti disturbi digestivi transitori (nausea e vomito) e solo in 2 casi il trattamento è stato interroto per eritema allergico. I risultati mostrano che il farmaco trova indicazione nei casi di emicrania comune, mentre non sembra influenzare significativamente l'andamento delle crisi di cefalea tensivo-vascolare.

Effectiveness of Aromatherapy for Relief of Pain, Nausea, and Vomiting after Percutaneous Nephrolithotomy: A Randomized Controlled Trial

2020 ◽  
Vol 27 (6) ◽  
pp. 440-448
Author(s):  
Mojdeh Amirhosseini ◽  
Mahlagha Dehghan ◽  
Parvin Mangolian Shahrbabaki ◽  
Hamid Pakmanesh
Keyword(s):  
Clinical Trial ◽  
Randomized Controlled Trial ◽  
Percutaneous Nephrolithotomy ◽  
Complementary Therapies ◽  
Controlled Trial ◽  
The Other ◽  
Nausea And Vomiting ◽  
Control Group ◽  
Analog Scale ◽  
Randomized Controlled

<b><i>Background:</i></b> Postoperative pain, nausea, and vomiting are common side effects of percutaneous nephrolithotomy. Nowadays, non-pharmacological and complementary therapies have been noticed. Therefore, a study was conducted to determine the effectiveness of lavender and clary sage on the pain, nausea, and vomiting after percutaneous nephrolithotomy. <b><i>Methods:</i></b> This is a randomized clinical trial study on 79 patients undergoing percutaneous nephrolithotomy. Patients were randomly divided into three groups of lavender aromatherapy (<i>n</i> = 27), clary sage aromatherapy (<i>n</i> = 26), and a control group (<i>n</i> = 26). Each of the intervention groups received the inhalation aromatherapy immediately and 3 and 6 h after the operation. Pain, nausea, and emetic episodes in patients of the three groups were measured before the intervention and 30 min after each intervention using a visual analog scale and checklist. <b><i>Results:</i></b> Pain decreased significantly in the clary sage aromatherapy group. Nausea had a downward trend in the two groups of aromatherapy. The lavender aromatherapy group had the lowest incidence of emetic episodes compared to the other groups. <b><i>Conclusion:</i></b> Regarding the annoying pain, nausea, and vomiting after percutaneous nephrolithotomy for patients, and taking into account the complications of drug therapy, the use of complementary non-pharmacological methods can help increase the comfort of patients.

Comparison of quince with vitamin B6 for treatment of nausea and vomiting in pregnancy: a randomised clinical trial

2017 ◽  
Vol 37 (8) ◽  
pp. 1048-1052 ◽  
Author(s):  
Effat Jafari-Dehkordi ◽  
Fataneh Hashem-Dabaghian ◽  
Fatemeh Aliasl ◽  
Jaleh Aliasl ◽  
Maryam Taghavi-Shirazi ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Vitamin B6 ◽  
Randomised Clinical Trial ◽  
Nausea And Vomiting ◽  
In Pregnancy
Sign in / Sign up

Export Citation Format

Share Document